Quick summary
Defensins are small (2-5 kDa) cationic antimicrobial peptides that form a frontline barrier of human innate immunity. Alpha-defensins are stored in neutrophils while beta-defensins protect epithelial surfaces, killing microbes through membrane disruption and bridging innate and adaptive immunity.
Overview
Defensins are a family of small (2–5 kDa) cationic antimicrobial peptides with a β-sheet core stabilized by three intramolecular disulfide bonds. Humans express alpha-defensins (in neutrophils and intestinal Paneth cells) and beta-defensins (in epithelial surfaces). They constitute a frontline barrier of innate immunity against bacteria, fungi, and enveloped viruses.
Mechanism of action
Defensins kill microbes primarily by disrupting microbial membranes. Their cationic, amphipathic structure enables electrostatic binding to negatively charged bacterial membranes, followed by insertion and pore formation that causes membrane disruption and leakage of intracellular contents. Beyond direct killing, defensins serve as immunomodulators: they chemoattract dendritic cells, T cells, and mast cells via CCR6 and other receptors, bridging innate and adaptive immunity. Alpha-defensins (HNP-1 to -4) are stored in neutrophil azurophilic granules and released during phagocytosis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| antimicrobial / wound research | topical | 1–10 mcg/mL | research use only | In vitro and ex vivo concentrations used in research; clinical dosing not established |
| systemic infection research | intravenous | 1–10 mg/kg | research use only |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Over 50 human defensin peptides have been characterized. Alpha-defensins HNP-1 to -4 comprise 5–7% of total neutrophil protein. Beta-defensins (HBD-1, -2, -3) are constitutively or inductively expressed on skin and mucosal surfaces. Research has linked defensin deficiency to increased susceptibility to Crohn's disease, atopic dermatitis, and recurrent infections. Therapeutic applications under investigation include topical antimicrobials for wound care, vaginal infections, and oral candidiasis. Retrocyclin (theta-defensin analog) shows HIV-neutralizing activity in vitro.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Defensins for synergistic effects.
Legal status
No defensin peptide is FDA-approved as a drug. Human neutrophil peptide HNP-1 and synthetic analogs are available as research reagents. Clinical trials of defensin-based formulations are in early phases.
Sourcing & access
Research compound
Defensins is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Defensins are a family of small cationic antimicrobial peptides with a beta-sheet core stabilized by three disulfide bonds. Humans express alpha-defensins (in neutrophils and intestinal Paneth cells) and beta-defensins (on epithelial surfaces) as part of the innate immune system.
Defensins kill microbes by disrupting their membranes through electrostatic binding to negatively charged bacterial surfaces, followed by insertion and pore formation. Beyond direct killing, they serve as immunomodulators that chemoattract dendritic cells, T cells, and mast cells, bridging innate and adaptive immunity.
Defensins can be cytotoxic to mammalian cells at high concentrations and may cause inflammatory responses at systemic doses. No defensin peptide is FDA-approved as a drug. Therapeutic applications under investigation include topical antimicrobials for wound care and oral candidiasis.
Research has linked defensin deficiency to increased susceptibility to Crohn's disease, atopic dermatitis, and recurrent infections. Alpha-defensins HNP-1 to -4 comprise 5-7% of total neutrophil protein, highlighting their importance in immune defense.